Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hanmi Pharm Co., Ltd. (128940:KRX), powered by AI.
Hanmi Pharm Co., Ltd. is currently trading at ₩446,500. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hanmi Pharm Co., Ltd. on Alpha Lenz.
Hanmi Pharm Co., Ltd.'s P/E ratio is 33.7.
“Hanmi Pharm Co., Ltd. trades at a P/E of 33.7 (premium valuation) with solid ROE of 14.5%.”
Ask for details →Hanmi Pharm Co., Ltd. is a prominent pharmaceutical company known for its innovative approach to drug development and manufacturing in South Korea. Its core function centers around researching and producing a wide array of pharmaceuticals, including innovative therapies and generics, aiming to treat a multitude of health conditions. Hanmi Pharm focuses on several therapeutic areas such as oncology, diabetes, and cardiovascular diseases, driving advancements with its cutting-edge proprietary technologies. The company is renowned for its robust R&D initiatives, evidenced by numerous patents and significant investments into creating biopharmaceuticals that cater to global health needs. In the financial market, Hanmi Pharm represents a staple in the healthcare sector, reflecting the dynamic nature of medical innovation and healthcare demand. With its headquarters strategically located in South Korea, the company not only impacts local pharmaceutical landscapes but also positions itself as a key player in the global market through strategic partnerships and international collaborations. Hanmi Pharm Co., Ltd. plays a crucial role in advancing medical treatments, contributing significantly to the pharmaceutical industry's growth and innovation.
“Hanmi Pharm Co., Ltd. trades at a P/E of 33.7 (premium valuation) with solid ROE of 14.5%.”
Ask for details →Hanmi Pharm Co., Ltd. (ticker: 128940) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,270 employees. Market cap is $5.7T.
The current price is ₩446,500 with a P/E ratio of 33.74x and P/B of 4.58x.
ROE is 14.53% and operating margin is 16.66%. Annual revenue is $1.5T.